*Result*: Artificial intelligence in inflammatory bowel disease: bridging innovation, implementation and impact.
Title:
Artificial intelligence in inflammatory bowel disease: bridging innovation, implementation and impact.
Authors:
Iacucci M; APC Microbiome Ireland, College of Medicine and Health, University College Cork, Cork, Ireland. miacucci@ucc.ie., Santacroce G; APC Microbiome Ireland, College of Medicine and Health, University College Cork, Cork, Ireland., Maeda Y; APC Microbiome Ireland, College of Medicine and Health, University College Cork, Cork, Ireland., Majumder S; APC Microbiome Ireland, College of Medicine and Health, University College Cork, Cork, Ireland., Hassan C; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.; Endoscopy Unit, Humanitas Clinical and Research Center IRCCS, Rozzano, Italy., Shung DL; Section of Digestive Diseases, Department of Medicine, Yale School of Medicine, New Haven, CT, USA.; Department of Biomedical Informatics and Data Science, Yale School of Medicine, New Haven, CT, USA., Stidham RW; Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA., Bisschops R; Division of Gastroenterology, University Hospitals Leuven, Leuven, Belgium., Naranjo V; Instituto de Investigación e Innovación en Bioingeniería, HUMAN-tech, Universitat Politècnica de València, València, Spain., Grisan E; School of Engineering Computer Science and Informatics, London South Bank University, London, UK., Ghosh S; APC Microbiome Ireland, College of Medicine and Health, University College Cork, Cork, Ireland.
Source:
Nature reviews. Gastroenterology & hepatology [Nat Rev Gastroenterol Hepatol] 2026 Mar 19. Date of Electronic Publication: 2026 Mar 19.
Publication Model:
Ahead of Print
Publication Type:
Journal Article; Review
Language:
English
Journal Info:
Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101500079 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1759-5053 (Electronic) Linking ISSN: 17595045 NLM ISO Abbreviation: Nat Rev Gastroenterol Hepatol Subsets: MEDLINE
Imprint Name(s):
Original Publication: London ; New York : Nature Pub. Group, c2009-
References:
Honap, S., Agrinier, N., Danese, S. & Peyrin-Biroulet, L. Disease prevention trials in IBD: feasibility to future outlook. Nat. Rev. Gastroenterol. Hepatol. 22, 1–2 (2025). (PMID: 3930477410.1038/s41575-024-00984-3)
Iacucci, M. et al. Artificial intelligence and endo-histo-omics: new dimensions of precision endoscopy and histology in inflammatory bowel disease. Lancet Gastroenterol. Hepatol. 9, 758–772 (2024). A landmark review defining the emerging ‘endo-histo-omics’ paradigm and providing a comprehensive conceptual framework for multimodal AI in IBD. (PMID: 3875966110.1016/S2468-1253(24)00053-0)
Santacroce, G. et al. Present and future of endoscopy precision for inflammatory bowel disease. Dig. Endosc. 36, 292–304 (2024). (PMID: 3764363510.1111/den.14672)
Iacucci, M., Maeda, Y., Santacroce, G. & Ghosh, S. AI-enabled ‘endo-histo-omics’: breaking down intestinal barriers in IBD. Nat. Rev. Gastroenterol. Hepatol. 22, 362–363 (2025). (PMID: 4003306210.1038/s41575-025-01051-1)
Iacucci, M. et al. Opening the doors of precision medicine: novel tools to assess intestinal barrier in inflammatory bowel disease and colitis-associated neoplasia. Gut 73, 1749–1762 (2024). (PMID: 388512941142279210.1136/gutjnl-2023-331579)
Stidham, R. W., Ghanem, L. R., Fletcher, J. G. & Bruining, D. H. Artificial intelligence-enabled clinical trials in inflammatory bowel disease: automating and enhancing disease assessment and study management. Gastroenterology 169, 432–443 (2025). (PMID: 401587391235007110.1053/j.gastro.2025.02.039)
Honap, S., Zou, G., Danese, S., Peyrin-Biroulet, L. & Jairath, V. Personalized (N-of-1) clinical trials for inflammatory bowel disease: opportunities and challenges. Clin. Gastroenterol. Hepatol. 23, 14–23 (2025). (PMID: 3930379910.1016/j.cgh.2024.08.028)
Silverman, A. L., Shung, D., Stidham, R. W., Kochhar, G. S. & Iacucci, M. How artificial intelligence will transform clinical care, research, and trials for inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 23, 428–439.e4 (2025). (PMID: 3899240610.1016/j.cgh.2024.05.048)
Ghersin, I. et al. Comparative evaluation of a language model and human specialists in the application of European guidelines for the management of inflammatory bowel diseases and malignancies. Endoscopy 56, 706–709 (2024). (PMID: 3849919710.1055/a-2289-5732)
Sciberras, M. et al. Accuracy of information given by ChatGPT for patients with inflammatory bowel disease in relation to ECCO Guidelines. J. Crohns Colitis 18, 1215–1221 (2024). (PMID: 3852039410.1093/ecco-jcc/jjae040)
Maeda, Y. et al. Evaluation in real-time use of artificial intelligence during colonoscopy to predict relapse of ulcerative colitis: a prospective study. Gastrointest. Endosc. 95, 747–756.e2 (2022). (PMID: 3469542210.1016/j.gie.2021.10.019)
Iacucci, M. et al. A virtual chromoendoscopy artificial intelligence system to detect endoscopic and histologic activity/remission and predict clinical outcomes in ulcerative colitis. Endoscopy 55, 332–341 (2023). (PMID: 3622864910.1055/a-1960-3645)
Maeda, Y. et al. Artificial intelligence-assisted colonoscopy to identify histologic remission and predict the outcomes of patients with ulcerative colitis: a systematic review. Dig. Liver Dis. 56, 1119–1125 (2024). (PMID: 3864302010.1016/j.dld.2024.04.005)
Dubinsky, M. C. et al. Challenges and opportunities in IBD clinical trial design. Gastroenterology 161, 400–404 (2021). (PMID: 3386479610.1053/j.gastro.2021.03.065)
Turner, D. et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 160, 1570–1583 (2021). (PMID: 3335909010.1053/j.gastro.2020.12.031)
Gottlieb, K. et al. Central reading of ulcerative colitis clinical trial videos using neural networks. Gastroenterology 160, 710–719.e2 (2021). (PMID: 3309888310.1053/j.gastro.2020.10.024)
Stidham, R. W. et al. Using computer vision to improve endoscopic disease quantification in therapeutic clinical trials of ulcerative colitis. Gastroenterology 166, 155–167.e2 (2024). A pivotal study validating AI-based cumulative activity quantification as a standardized, scalable end point for ulcerative colitis clinical trials. (PMID: 3783292410.1053/j.gastro.2023.09.049)
Iacucci, M. et al. Detection, localisation, and quantification of neutrophils to assess disease activity and early response to therapy in ulcerative colitis: a novel AI-driven model. EClinicalMedicine 90, 103658 (2025). This study pioneers automated neutrophil quantification as a real-time biomarker of early treatment response in ulcerative colitis. (PMID: 413994731270204410.1016/j.eclinm.2025.103658)
Sahoo, D. et al. Artificial intelligence guided discovery of a barrier-protective therapy in inflammatory bowel disease. Nat. Commun. 12, 4246 (2021). (PMID: 34253728827568310.1038/s41467-021-24470-5)
Iacucci, M. & Santacroce, G. Multi-OMICs orchestration enabled by artificial intelligence in inflammatory bowel disease: an exciting future. United European Gastroenterol. J. 12, 1350–1351 (2024). (PMID: 395083131165231910.1002/ueg2.12663)
Ben-Horin, S. et al. Capsule endoscopy-guided proactive treat-to-target versus continued standard care in patients with quiescent Crohn’s disease: a randomized controlled trial. Gastroenterology 169, 85–93.e3 (2025). (PMID: 4010751910.1053/j.gastro.2025.02.031)
Bin, Y., Peng, R., Lee, Y., Lee, Z. & Liu, Y. Artificial intelligence-assisted capsule endoscopy for detecting lesions in Crohn’s disease: a systematic review and meta-analysis. Front. Artif. Intell. 8, 1531362 (2025). (PMID: 402358581199679710.3389/frai.2025.1531362)
Brodersen, J. B. et al. Artificial intelligence-assisted analysis of pan-enteric capsule endoscopy in patients with suspected Crohn’s disease: a study on diagnostic performance. J. Crohns Colitis 18, 75–81 (2024). (PMID: 3752755410.1093/ecco-jcc/jjad131)
Wang, X. et al. Machine learning models based on CT enterography for differentiating between ulcerative colitis and colonic Crohn’s disease using intestinal wall, mesenteric fat, and visceral fat features. Acad. Radiol. 32, 5860–5868 (2025). (PMID: 4055563910.1016/j.acra.2025.06.005)
Chirra, P. V. et al. Developing a reproducible radiomics model for diagnosis of active Crohn’s disease on CT enterography across annotation variations and acquisition differences. J. Imaging Inform. Med. 38, 1594–1605 (2024). (PMID: 394665071209232010.1007/s10278-024-01303-7)
Yu, L., Cai, Y., Lin, S., Zhang, H. & Yu, S. Quantitative MRI radiomics approach for evaluating muscular alteration in Crohn disease: development of a machine learning-nomogram composite diagnostic tool. Abdom. Radiol. 50, 5069–5078 (2025). (PMID: 10.1007/s00261-025-04896-x)
Furlanello, C. et al. The development of artificial intelligence in the histological diagnosis of inflammatory bowel disease (IBD-AI). Dig. Liver Dis. 57, 184–189 (2025). (PMID: 3885309310.1016/j.dld.2024.05.033)
Cai, C. et al. IBDAIM: Artificial intelligence for analyzing intestinal biopsies pathological images for assisted integrated diagnostic of inflammatory bowel disease. Int. J. Med. Inform. 203, 106024 (2025). (PMID: 4058068810.1016/j.ijmedinf.2025.106024)
Mossotto, E. et al. Classification of paediatric inflammatory bowel disease using machine learning. Sci. Rep. 7, 2427 (2017). (PMID: 28546534544507610.1038/s41598-017-02606-2)
Grännö, O. et al. Preclinical protein signatures of Crohn’s disease and ulcerative colitis: a nested case-control study within large population-based cohorts. Gastroenterology 168, 741–753 (2025). A major multicohort study identifying proteomic signatures that predict future IBD onset, shaping early-intervention strategies. (PMID: 3960868310.1053/j.gastro.2024.11.006)
Rimondi, A. et al. Can artificial intelligence replace endoscopists when assessing mucosal healing in ulcerative colitis? A systematic review and diagnostic test accuracy meta-analysis. Dig. Liver Dis. 56, 1164–1172 (2024). (PMID: 3805721810.1016/j.dld.2023.11.005)
Ruan, G. C. et al. External validation of the Paddington International Virtual Electronic ChromoendoScopy ScOre as a good endoscopic score to define mucosal healing and predict long-term clinical outcomes in ulcerative colitis. J. Dig. Dis. 23, 446–454 (2022). (PMID: 3612130810.1111/1751-2980.13126)
Kuroki, T. et al. A novel artificial intelligence-assisted “vascular healing” diagnosis for prediction of future clinical relapse in patients with ulcerative colitis: a prospective cohort study (with video). Gastrointest. Endosc. 100, 97–108 (2024). (PMID: 3821585910.1016/j.gie.2024.01.010)
Iacucci, M. et al. A novel switching of artificial intelligence to generate simultaneously multimodal images to assess inflammation and predict outcomes in ulcerative colitis — (with video). Dig. Endosc. 37, 1078–1088 (2025). (PMID: 405189241251191810.1111/den.15067)
Iacucci, M. et al. Computer-aided imaging analysis of probe-based confocal laser endomicroscopy with molecular labeling and gene expression identifies markers of response to biological therapy in IBD patients: the Endo-Omics Study. Inflamm. Bowel Dis. 29, 1409–1420 (2023). (PMID: 363784981047274510.1093/ibd/izac233)
Puga-Tejada, M. et al. Artificial intelligence-enabled histology exhibits comparable accuracy to pathologists in assessing histological remission in ulcerative colitis: a systematic review, meta-analysis, and meta-regression. J. Crohns Colitis 19, jjae198 (2025). (PMID: 397423951172418810.1093/ecco-jcc/jjae198)
Iacucci, M. et al. Artificial intelligence enabled histological prediction of remission or activity and clinical outcomes in ulcerative colitis. Gastroenterology 164, 1180–1188.e2 (2023). (PMID: 3687159810.1053/j.gastro.2023.02.031)
Ohara, J. et al. Deep learning-based automated quantification of goblet cell mucus using histological images as a predictor of clinical relapse of ulcerative colitis with endoscopic remission. J. Gastroenterol. 57, 962–970 (2022). (PMID: 3618470110.1007/s00535-022-01924-1)
Ohara, J. et al. Automated neutrophil quantification and histological score estimation in ulcerative colitis. Clin. Gastroenterol. Hepatol. 23, 846–854.e7 (2025). (PMID: 3905954510.1016/j.cgh.2024.06.040)
Santacroce, G. et al. P406 A novel active learning-based digital pathology protocol annotation for histologic assessment in ulcerative colitis using PICaSSO Histologic Remission Index (PHRI). J. Crohns Colitis 18, i835–i836 (2024). (PMID: 10.1093/ecco-jcc/jjad212.0536)
Xue, Z. et al. Integrative mapping of human CD8<sup>+</sup> T cells in inflammation and cancer. Nat. Methods 22, 435–445 (2025). (PMID: 3961411110.1038/s41592-024-02530-0)
Majumder, S. et al. Endocytoscopy with automated multispectral intestinal barrier pathology imaging for assessment of deep healing to predict outcomes in ulcerative colitis. Gut 73, 1603–1606 (2024). A seminal proof-of-concept introducing real-time barrier imaging as a new therapeutic target and outcome measure in ulcerative colitis. (PMID: 391070871142323410.1136/gutjnl-2024-332894)
Kumaralingam, L. et al. Artificial intelligence-assisted approach to assessing bowel wall thickness in pediatric inflammatory bowel disease using intestinal ultrasound images. J. Crohns Colitis 19, jjaf037 (2025). (PMID: 400525321197671210.1093/ecco-jcc/jjaf037)
Stidham, R. W. et al. Artificial intelligence for quantifying cumulative small bowel disease severity on CT-enterography in Crohn’s disease. Am. J. Gastroenterol. 119, 1885–1893 (2024). (PMID: 386611481157925310.14309/ajg.0000000000002828)
Ogata, N. et al. Artificial Intelligence-assisted video colonoscopy for disease monitoring of ulcerative colitis: a prospective study. J. Crohns Colitis 19, jjae080 (2025). (PMID: 388287341172552510.1093/ecco-jcc/jjae080)
Liu, X. et al. Machine learning–based prediction of pediatric ulcerative colitis treatment response using diagnostic histopathology. Gastroenterology 166, 921–924.e4 (2024). (PMID: 383096311183676810.1053/j.gastro.2024.01.033)
Zhang, J., Qin, S. & Jiang, H. CT-based delta-radiomics signature of visceral adipose tissue for prediction of disease progression in ileal stricturing Crohn’s disease. Jpn. J. Radiol. 43, 1335–1346 (2025). (PMID: 4021491310.1007/s11604-025-01779-5)
Li, X. et al. Longitudinal computed tomography-based delta-radiomics of visceral adipose tissue predicts infliximab secondary loss of response in Crohn’s disease patients. World J. Gastroenterol. 31, 105895 (2025). (PMID: 405385121217584410.3748/wjg.v31.i21.105895)
Iacucci, M., Maeda, Y. & Ghosh, S. A baby step or a real giant stride: histomic enabled by artificial intelligence to predict treatment response in pediatric patients with ulcerative colitis. Gastroenterology 166, 730–732 (2024). (PMID: 3846060810.1053/j.gastro.2024.03.004)
Schreiber, S. et al. Machine learning-based precision medicine approach identifies specific responder sub-populations in patients treated with vedolizumab by dynamic clustering of Pro-2 data: post hoc analysis of VARSiTY and confirmation in the GEMINI dataset [abstract Sa1773]. Gastroenterology 166, S-517 (2024). (PMID: 10.1016/S0016-5085(24)01658-5)
Guerrero Vinsard, D. et al. Development of an artificial intelligence tool for detecting colorectal lesions in inflammatory bowel disease. IGIE 2, 91–101.e6 (2023). (PMID: 416476181285077010.1016/j.igie.2023.03.004)
Abdelrahim, M. et al. New AI model for neoplasia detection and characterisation in inflammatory bowel disease. Gut 73, 725–728 (2024). A pivotal study introducing a novel AI model capable of accurately detecting and characterizing neoplasia in IBD, marking a major advance in dysplasia surveillance and cancer prevention. (PMID: 3839543810.1136/gutjnl-2023-330718)
Noguchi, T. et al. Artificial intelligence program to predict p53 mutations in ulcerative colitis-associated cancer or dysplasia. Inflamm. Bowel Dis. 28, 1072–1080 (2022). (PMID: 3527808110.1093/ibd/izab350)
Iacucci, M. et al. Endo-histo foundational fusion model: a novel artificial intelligence for assessing histologic remission and response to therapy in ulcerative colitis clinical trial. J. Crohns Colitis 19, jjaf108 (2025). The first AI model to fuse endoscopic and histologic information using foundational architectures, bringing the concept of unified endo-histo remission closer to implementation in clinical trials and routine practice. (PMID: 405813391223920210.1093/ecco-jcc/jjaf108)
Horn, V. et al. Multimodal profiling of peripheral blood identifies proliferating circulating effector CD4<sup>+</sup> T cells as predictors for response to integrin α4β7-blocking therapy in inflammatory bowel disease. Gastroenterology 168, 327–343 (2025). (PMID: 3934325010.1053/j.gastro.2024.09.021)
Preto, A. J. et al. Multi-omics data integration identifies novel biomarkers and patient subgroups in inflammatory bowel disease. J. Crohns Colitis 19, jjae197 (2025). (PMID: 397564191179289210.1093/ecco-jcc/jjae197)
Neurath, M. F. & Vieth, M. Different levels of healing in inflammatory bowel diseases: mucosal, histological, transmural, barrier and complete healing. Gut 72, 2164–2183 (2023). (PMID: 3764044310.1136/gutjnl-2023-329964)
Iacucci, M. et al. Automated real-time imaging of intestinal barrier integrity and molecular profiling for early outcome prediction in inflammatory bowel disease — Endo-Histo-Barrier-Omics study. J. Crohns Colitis 19, jjaf200 (2025). A breakthrough study showing automated, real-time barrier imaging integrated with molecular profiling to enable deep characterization and early prediction of clinical outcomes in IBD. (PMID: 412596661270188910.1093/ecco-jcc/jjaf200)
Hirten, R. P. et al. Physiological data collected from wearable devices identify and predict inflammatory bowel disease flares. Gastroenterology 168, 939–951.e5 (2025). The first major study showing that wearable-derived physiological signatures can detect and predict IBD flares in real time. (PMID: 398266191220637910.1053/j.gastro.2024.12.024)
Lee, J. W. et al. Deep learning model using stool pictures for predicting eEndoscopic mucosal inflammation in patients with ulcerative colitis. Am. J. Gastroenterol. 120, 213–224 (2025). (PMID: 3905164810.14309/ajg.0000000000002978)
Singh, S. et al. AGA living clinical practice guideline on pharmacological management of moderate-to-severe ulcerative colitis. Gastroenterology 167, 1307–1343 (2024). (PMID: 395721321216214210.1053/j.gastro.2024.10.001)
Patel, P. V. et al. Large language models outperform traditional natural language processing methods in extracting patient-reported outcomes in inflammatory bowel disease. Gastro. Hep Adv. 4, 100563 (2025). (PMID: 3987786510.1016/j.gastha.2024.10.003)
Dai, J. et al. Comparative analysis of natural language processing methodologies for classifying computed tomography enterography reports in Crohn’s disease patients. npj Digit. Med. 8, 324 (2025). (PMID: 404422941212286710.1038/s41746-025-01729-5)
Silverman, A. L. et al. Algorithmic identification of treatment-emergent adverse events from clinical notes using large language models: a pilot study in inflammatory bowel disease. Clin. Pharmacol. Ther. 115, 1391–1399 (2024). (PMID: 384597191109070910.1002/cpt.3226)
Yan, Z. et al. Ability of ChatGPT to replace doctors in patient education: cross-sectional comparative analysis of inflammatory bowel disease. J. Med. Internet Res. 27, e62857 (2025). (PMID: 401638531199752710.2196/62857)
Ozturk, O. et al. Assessing ChatGPT-v4 for guideline-concordant inflammatory bowel disease: accuracy, completeness, and temporal drift. J. Clin. Med. 14, 4599 (2025). (PMID: 406489731225003910.3390/jcm14134599)
Naqvi, H. A. et al. Evaluation of online chat-based artificial intelligence responses about inflammatory bowel disease and diet. Eur. J. Gastroenterol. Hepatol. 36, 1109–1112 (2024). (PMID: 3897352810.1097/MEG.0000000000002815)
Zhang, Y. et al. Evaluating large language models as patient education tools for inflammatory bowel disease: a comparative study. World J. Gastroenterol. 31, 102090 (2025). (PMID: 3995845011752706)
Levartovsky, A. et al. Enhancing diagnostics: ChatGPT-4 performance in ulcerative colitis endoscopic assessment. Endosc. Int. Open. 13, a-2542–0943 (2025). A key study demonstrating that LLMs can approximate expert endoscopic scoring, signalling a new frontier for AI–clinician hybrid systems.
US Food and Drug Administration. Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations — Draft Guidance for Industry and Food and Drug Administration Staff (FDA, 2025).
Omar, M. et al. Sociodemographic biases in medical decision making by large language models. Nat. Med. 31, 1873–1881 (2025). (PMID: 4019544810.1038/s41591-025-03626-6)
Stidham, R. W. & Takenaka, K. Artificial intelligence for disease assessment in inflammatory bowel disease: how will it change our practice? Gastroenterology 162, 1493–1506 (2022). (PMID: 34995537899718610.1053/j.gastro.2021.12.238)
Tham, S. et al. Knowledge, perceptions and behaviours of endoscopists towards the use of artificial intelligence-aided colonoscopy. Surg. Endosc. 37, 7395–7400 (2023). (PMID: 3767019110.1007/s00464-023-10412-3)
Urban, G. et al. Deep learning localizes and identifies polyps in real time with 96% accuracy in screening colonoscopy. Gastroenterology 155, 1069–1078.e8 (2018). (PMID: 29928897617410210.1053/j.gastro.2018.06.037)
Areia, M. et al. Cost-effectiveness of artificial intelligence for screening colonoscopy: a modelling study. Lancet Digit. Health 4, e436–e444 (2022). (PMID: 3543015110.1016/S2589-7500(22)00042-5)
Patel, H. K. et al. Lack of effectiveness of computer aided detection for colorectal neoplasia: a systematic review and meta-analysis of nonrandomized studies. Clin. Gastroenterol. Hepatol. 22, 971–980.e15 (2024). (PMID: 3805680310.1016/j.cgh.2023.11.029)
Yao, L. et al. Effect of artificial intelligence on novice-performed colonoscopy: a multicenter randomized controlled tandem study. Gastrointest. Endosc. 99, 91–99.e9 (2024). (PMID: 3753663510.1016/j.gie.2023.07.044)
Grover, S. C. & Walsh, C. M. Integrating artificial intelligence into endoscopy training: opportunities, challenges, and strategies. Lancet Gastroenterol. Hepatol. 9, 11–13 (2024). (PMID: 3783257010.1016/S2468-1253(23)00309-6)
Van Der Velden, B. H. M., Kuijf, H. J., Gilhuijs, K. G. A. & Viergever, M. A. Explainable artificial intelligence (XAI) in deep learning-based medical image analysis. Med. Image Anal. 79, 102470 (2022). (PMID: 3557682110.1016/j.media.2022.102470)
Singh, S. P., Anirvan, P. & Meher, D. Artificial intelligence in gastrointestinal endoscopy in a resource-constrained setting: a reality check. Euroasian J. Hepatogastroenterol. 10, 92–97 (2021). (PMID: 10.5005/jp-journals-10018-1322)
Norori, N., Hu, Q., Aellen, F. M., Faraci, F. D. & Tzovara, A. Addressing bias in big data and AI for health care: a call for open science. Patterns 2, 100347 (2021). (PMID: 34693373851500210.1016/j.patter.2021.100347)
Nigam, G. et al. Survey on the use of artificial intelligence in IBD patients in the USA and UK [abstract PMO-10]. Gut 70, A80 (2021).
Heidt, A. Intellectual property and data privacy: the hidden risks of AI. Nature https://doi.org/10.1038/d41586-024-02838-z (2024).
Kamulegeya, L. et al. Using artificial intelligence on dermatology conditions in Uganda: a case for diversity in training data sets for machine learning. Afr. Health Sci. 23, 753–763 (2023). (PMID: 382235941078228910.4314/ahs.v23i2.86)
Huanbutta, K. et al. Artificial intelligence-driven pharmaceutical industry: a paradigm shift in drug discovery, formulation development, manufacturing, quality control, and post-market surveillance. Eur. J. Pharm. Sci. 203, 106938 (2024). (PMID: 3941912910.1016/j.ejps.2024.106938)
Chhina, A. et al. Revolutionizing pharmaceutical industry: the radical impact of artificial intelligence and machine learning. Curr. Pharm. Des. 29, 1645–1658 (2023). (PMID: 3755090410.2174/1381612829666230807161421)
Lee, D. & Yoon, S. N. Application of artificial intelligence-based technologies in the healthcare industry: opportunities and challenges. Int. J. Environ. Res. Pubic Health 18, 271 (2021). (PMID: 10.3390/ijerph18010271)
Richie, C. Environmentally sustainable development and use of artificial intelligence in health care. Bioethics 36, 547–555 (2022). (PMID: 35290675931165410.1111/bioe.13018)
Ueda, D. et al. Climate change and artificial intelligence in healthcare: review and recommendations towards a sustainable future. Diagn. Interv. Imaging 105, 453–459 (2024). (PMID: 3891812310.1016/j.diii.2024.06.002)
Sarkar, S. et al. Carbon footprint reduction for sustainable data centers in real-time. In Proc. 38th AAAI Conf. Artif. Intell. 22322–22330 (AAAI Press, 2024).
Maeda, Y. et al. Fully automated diagnostic system with artificial intelligence using endocytoscopy to identify the presence of histologic inflammation associated with ulcerative colitis (with video). Gastrointest. Endosc. 89, 408–415 (2019). (PMID: 3026854210.1016/j.gie.2018.09.024)
Bossuyt, P. et al. Automatic, computer-aided determination of endoscopic and histological inflammation in patients with mild to moderate ulcerative colitis based on red density. Gut 69, 1778–1786 (2020). (PMID: 3191523710.1136/gutjnl-2019-320056)
Seager, A. et al. Polyp detection with colonoscopy assisted by the GI Genius artificial intelligence endoscopy module compared with standard colonoscopy in routine colonoscopy practice (COLO-DETECT): a multicentre, open-label, parallel-arm, pragmatic randomised controlled trial. Lancet Gastroenterol. Hepatol. 9, 911–923 (2024). (PMID: 3915349110.1016/S2468-1253(24)00161-4)
White, C. D. et al. A deep learning approach to case prioritisation of colorectal biopsies. Histopathology 86, 373–384 (2025). (PMID: 3936057910.1111/his.15331)
Wei, Y. et al. Focal liver lesion diagnosis with deep learning and multistage CT imaging. Nat. Commun. 15, 7040 (2024). (PMID: 391477671132734410.1038/s41467-024-51260-6)
Mannucci, A. et al. Prediction of long-term recurrence-free and overall survival in early-onset colorectal cancer: the ENCORE multi-centre study. npj Precis. Oncol. 9, 202 (2025). (PMID: 405441801218258810.1038/s41698-025-00978-7)
Jiang, X. et al. End-to-end prognostication in colorectal cancer by deep learning: a retrospective, multicentre study. Lancet Digit. Health 6, e33–e43 (2024). (PMID: 3812325410.1016/S2589-7500(23)00208-X)
Higgins, K. et al. The Helicobacter pylori AI-clinician harnesses artificial intelligence to personalise H. pylori treatment recommendations. Nat. Commun. 16, 6472 (2025). (PMID: 406596121225989910.1038/s41467-025-61329-5)
Iacucci, M. et al. Artificial intelligence and endo-histo-omics: new dimensions of precision endoscopy and histology in inflammatory bowel disease. Lancet Gastroenterol. Hepatol. 9, 758–772 (2024). A landmark review defining the emerging ‘endo-histo-omics’ paradigm and providing a comprehensive conceptual framework for multimodal AI in IBD. (PMID: 3875966110.1016/S2468-1253(24)00053-0)
Santacroce, G. et al. Present and future of endoscopy precision for inflammatory bowel disease. Dig. Endosc. 36, 292–304 (2024). (PMID: 3764363510.1111/den.14672)
Iacucci, M., Maeda, Y., Santacroce, G. & Ghosh, S. AI-enabled ‘endo-histo-omics’: breaking down intestinal barriers in IBD. Nat. Rev. Gastroenterol. Hepatol. 22, 362–363 (2025). (PMID: 4003306210.1038/s41575-025-01051-1)
Iacucci, M. et al. Opening the doors of precision medicine: novel tools to assess intestinal barrier in inflammatory bowel disease and colitis-associated neoplasia. Gut 73, 1749–1762 (2024). (PMID: 388512941142279210.1136/gutjnl-2023-331579)
Stidham, R. W., Ghanem, L. R., Fletcher, J. G. & Bruining, D. H. Artificial intelligence-enabled clinical trials in inflammatory bowel disease: automating and enhancing disease assessment and study management. Gastroenterology 169, 432–443 (2025). (PMID: 401587391235007110.1053/j.gastro.2025.02.039)
Honap, S., Zou, G., Danese, S., Peyrin-Biroulet, L. & Jairath, V. Personalized (N-of-1) clinical trials for inflammatory bowel disease: opportunities and challenges. Clin. Gastroenterol. Hepatol. 23, 14–23 (2025). (PMID: 3930379910.1016/j.cgh.2024.08.028)
Silverman, A. L., Shung, D., Stidham, R. W., Kochhar, G. S. & Iacucci, M. How artificial intelligence will transform clinical care, research, and trials for inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 23, 428–439.e4 (2025). (PMID: 3899240610.1016/j.cgh.2024.05.048)
Ghersin, I. et al. Comparative evaluation of a language model and human specialists in the application of European guidelines for the management of inflammatory bowel diseases and malignancies. Endoscopy 56, 706–709 (2024). (PMID: 3849919710.1055/a-2289-5732)
Sciberras, M. et al. Accuracy of information given by ChatGPT for patients with inflammatory bowel disease in relation to ECCO Guidelines. J. Crohns Colitis 18, 1215–1221 (2024). (PMID: 3852039410.1093/ecco-jcc/jjae040)
Maeda, Y. et al. Evaluation in real-time use of artificial intelligence during colonoscopy to predict relapse of ulcerative colitis: a prospective study. Gastrointest. Endosc. 95, 747–756.e2 (2022). (PMID: 3469542210.1016/j.gie.2021.10.019)
Iacucci, M. et al. A virtual chromoendoscopy artificial intelligence system to detect endoscopic and histologic activity/remission and predict clinical outcomes in ulcerative colitis. Endoscopy 55, 332–341 (2023). (PMID: 3622864910.1055/a-1960-3645)
Maeda, Y. et al. Artificial intelligence-assisted colonoscopy to identify histologic remission and predict the outcomes of patients with ulcerative colitis: a systematic review. Dig. Liver Dis. 56, 1119–1125 (2024). (PMID: 3864302010.1016/j.dld.2024.04.005)
Dubinsky, M. C. et al. Challenges and opportunities in IBD clinical trial design. Gastroenterology 161, 400–404 (2021). (PMID: 3386479610.1053/j.gastro.2021.03.065)
Turner, D. et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 160, 1570–1583 (2021). (PMID: 3335909010.1053/j.gastro.2020.12.031)
Gottlieb, K. et al. Central reading of ulcerative colitis clinical trial videos using neural networks. Gastroenterology 160, 710–719.e2 (2021). (PMID: 3309888310.1053/j.gastro.2020.10.024)
Stidham, R. W. et al. Using computer vision to improve endoscopic disease quantification in therapeutic clinical trials of ulcerative colitis. Gastroenterology 166, 155–167.e2 (2024). A pivotal study validating AI-based cumulative activity quantification as a standardized, scalable end point for ulcerative colitis clinical trials. (PMID: 3783292410.1053/j.gastro.2023.09.049)
Iacucci, M. et al. Detection, localisation, and quantification of neutrophils to assess disease activity and early response to therapy in ulcerative colitis: a novel AI-driven model. EClinicalMedicine 90, 103658 (2025). This study pioneers automated neutrophil quantification as a real-time biomarker of early treatment response in ulcerative colitis. (PMID: 413994731270204410.1016/j.eclinm.2025.103658)
Sahoo, D. et al. Artificial intelligence guided discovery of a barrier-protective therapy in inflammatory bowel disease. Nat. Commun. 12, 4246 (2021). (PMID: 34253728827568310.1038/s41467-021-24470-5)
Iacucci, M. & Santacroce, G. Multi-OMICs orchestration enabled by artificial intelligence in inflammatory bowel disease: an exciting future. United European Gastroenterol. J. 12, 1350–1351 (2024). (PMID: 395083131165231910.1002/ueg2.12663)
Ben-Horin, S. et al. Capsule endoscopy-guided proactive treat-to-target versus continued standard care in patients with quiescent Crohn’s disease: a randomized controlled trial. Gastroenterology 169, 85–93.e3 (2025). (PMID: 4010751910.1053/j.gastro.2025.02.031)
Bin, Y., Peng, R., Lee, Y., Lee, Z. & Liu, Y. Artificial intelligence-assisted capsule endoscopy for detecting lesions in Crohn’s disease: a systematic review and meta-analysis. Front. Artif. Intell. 8, 1531362 (2025). (PMID: 402358581199679710.3389/frai.2025.1531362)
Brodersen, J. B. et al. Artificial intelligence-assisted analysis of pan-enteric capsule endoscopy in patients with suspected Crohn’s disease: a study on diagnostic performance. J. Crohns Colitis 18, 75–81 (2024). (PMID: 3752755410.1093/ecco-jcc/jjad131)
Wang, X. et al. Machine learning models based on CT enterography for differentiating between ulcerative colitis and colonic Crohn’s disease using intestinal wall, mesenteric fat, and visceral fat features. Acad. Radiol. 32, 5860–5868 (2025). (PMID: 4055563910.1016/j.acra.2025.06.005)
Chirra, P. V. et al. Developing a reproducible radiomics model for diagnosis of active Crohn’s disease on CT enterography across annotation variations and acquisition differences. J. Imaging Inform. Med. 38, 1594–1605 (2024). (PMID: 394665071209232010.1007/s10278-024-01303-7)
Yu, L., Cai, Y., Lin, S., Zhang, H. & Yu, S. Quantitative MRI radiomics approach for evaluating muscular alteration in Crohn disease: development of a machine learning-nomogram composite diagnostic tool. Abdom. Radiol. 50, 5069–5078 (2025). (PMID: 10.1007/s00261-025-04896-x)
Furlanello, C. et al. The development of artificial intelligence in the histological diagnosis of inflammatory bowel disease (IBD-AI). Dig. Liver Dis. 57, 184–189 (2025). (PMID: 3885309310.1016/j.dld.2024.05.033)
Cai, C. et al. IBDAIM: Artificial intelligence for analyzing intestinal biopsies pathological images for assisted integrated diagnostic of inflammatory bowel disease. Int. J. Med. Inform. 203, 106024 (2025). (PMID: 4058068810.1016/j.ijmedinf.2025.106024)
Mossotto, E. et al. Classification of paediatric inflammatory bowel disease using machine learning. Sci. Rep. 7, 2427 (2017). (PMID: 28546534544507610.1038/s41598-017-02606-2)
Grännö, O. et al. Preclinical protein signatures of Crohn’s disease and ulcerative colitis: a nested case-control study within large population-based cohorts. Gastroenterology 168, 741–753 (2025). A major multicohort study identifying proteomic signatures that predict future IBD onset, shaping early-intervention strategies. (PMID: 3960868310.1053/j.gastro.2024.11.006)
Rimondi, A. et al. Can artificial intelligence replace endoscopists when assessing mucosal healing in ulcerative colitis? A systematic review and diagnostic test accuracy meta-analysis. Dig. Liver Dis. 56, 1164–1172 (2024). (PMID: 3805721810.1016/j.dld.2023.11.005)
Ruan, G. C. et al. External validation of the Paddington International Virtual Electronic ChromoendoScopy ScOre as a good endoscopic score to define mucosal healing and predict long-term clinical outcomes in ulcerative colitis. J. Dig. Dis. 23, 446–454 (2022). (PMID: 3612130810.1111/1751-2980.13126)
Kuroki, T. et al. A novel artificial intelligence-assisted “vascular healing” diagnosis for prediction of future clinical relapse in patients with ulcerative colitis: a prospective cohort study (with video). Gastrointest. Endosc. 100, 97–108 (2024). (PMID: 3821585910.1016/j.gie.2024.01.010)
Iacucci, M. et al. A novel switching of artificial intelligence to generate simultaneously multimodal images to assess inflammation and predict outcomes in ulcerative colitis — (with video). Dig. Endosc. 37, 1078–1088 (2025). (PMID: 405189241251191810.1111/den.15067)
Iacucci, M. et al. Computer-aided imaging analysis of probe-based confocal laser endomicroscopy with molecular labeling and gene expression identifies markers of response to biological therapy in IBD patients: the Endo-Omics Study. Inflamm. Bowel Dis. 29, 1409–1420 (2023). (PMID: 363784981047274510.1093/ibd/izac233)
Puga-Tejada, M. et al. Artificial intelligence-enabled histology exhibits comparable accuracy to pathologists in assessing histological remission in ulcerative colitis: a systematic review, meta-analysis, and meta-regression. J. Crohns Colitis 19, jjae198 (2025). (PMID: 397423951172418810.1093/ecco-jcc/jjae198)
Iacucci, M. et al. Artificial intelligence enabled histological prediction of remission or activity and clinical outcomes in ulcerative colitis. Gastroenterology 164, 1180–1188.e2 (2023). (PMID: 3687159810.1053/j.gastro.2023.02.031)
Ohara, J. et al. Deep learning-based automated quantification of goblet cell mucus using histological images as a predictor of clinical relapse of ulcerative colitis with endoscopic remission. J. Gastroenterol. 57, 962–970 (2022). (PMID: 3618470110.1007/s00535-022-01924-1)
Ohara, J. et al. Automated neutrophil quantification and histological score estimation in ulcerative colitis. Clin. Gastroenterol. Hepatol. 23, 846–854.e7 (2025). (PMID: 3905954510.1016/j.cgh.2024.06.040)
Santacroce, G. et al. P406 A novel active learning-based digital pathology protocol annotation for histologic assessment in ulcerative colitis using PICaSSO Histologic Remission Index (PHRI). J. Crohns Colitis 18, i835–i836 (2024). (PMID: 10.1093/ecco-jcc/jjad212.0536)
Xue, Z. et al. Integrative mapping of human CD8<sup>+</sup> T cells in inflammation and cancer. Nat. Methods 22, 435–445 (2025). (PMID: 3961411110.1038/s41592-024-02530-0)
Majumder, S. et al. Endocytoscopy with automated multispectral intestinal barrier pathology imaging for assessment of deep healing to predict outcomes in ulcerative colitis. Gut 73, 1603–1606 (2024). A seminal proof-of-concept introducing real-time barrier imaging as a new therapeutic target and outcome measure in ulcerative colitis. (PMID: 391070871142323410.1136/gutjnl-2024-332894)
Kumaralingam, L. et al. Artificial intelligence-assisted approach to assessing bowel wall thickness in pediatric inflammatory bowel disease using intestinal ultrasound images. J. Crohns Colitis 19, jjaf037 (2025). (PMID: 400525321197671210.1093/ecco-jcc/jjaf037)
Stidham, R. W. et al. Artificial intelligence for quantifying cumulative small bowel disease severity on CT-enterography in Crohn’s disease. Am. J. Gastroenterol. 119, 1885–1893 (2024). (PMID: 386611481157925310.14309/ajg.0000000000002828)
Ogata, N. et al. Artificial Intelligence-assisted video colonoscopy for disease monitoring of ulcerative colitis: a prospective study. J. Crohns Colitis 19, jjae080 (2025). (PMID: 388287341172552510.1093/ecco-jcc/jjae080)
Liu, X. et al. Machine learning–based prediction of pediatric ulcerative colitis treatment response using diagnostic histopathology. Gastroenterology 166, 921–924.e4 (2024). (PMID: 383096311183676810.1053/j.gastro.2024.01.033)
Zhang, J., Qin, S. & Jiang, H. CT-based delta-radiomics signature of visceral adipose tissue for prediction of disease progression in ileal stricturing Crohn’s disease. Jpn. J. Radiol. 43, 1335–1346 (2025). (PMID: 4021491310.1007/s11604-025-01779-5)
Li, X. et al. Longitudinal computed tomography-based delta-radiomics of visceral adipose tissue predicts infliximab secondary loss of response in Crohn’s disease patients. World J. Gastroenterol. 31, 105895 (2025). (PMID: 405385121217584410.3748/wjg.v31.i21.105895)
Iacucci, M., Maeda, Y. & Ghosh, S. A baby step or a real giant stride: histomic enabled by artificial intelligence to predict treatment response in pediatric patients with ulcerative colitis. Gastroenterology 166, 730–732 (2024). (PMID: 3846060810.1053/j.gastro.2024.03.004)
Schreiber, S. et al. Machine learning-based precision medicine approach identifies specific responder sub-populations in patients treated with vedolizumab by dynamic clustering of Pro-2 data: post hoc analysis of VARSiTY and confirmation in the GEMINI dataset [abstract Sa1773]. Gastroenterology 166, S-517 (2024). (PMID: 10.1016/S0016-5085(24)01658-5)
Guerrero Vinsard, D. et al. Development of an artificial intelligence tool for detecting colorectal lesions in inflammatory bowel disease. IGIE 2, 91–101.e6 (2023). (PMID: 416476181285077010.1016/j.igie.2023.03.004)
Abdelrahim, M. et al. New AI model for neoplasia detection and characterisation in inflammatory bowel disease. Gut 73, 725–728 (2024). A pivotal study introducing a novel AI model capable of accurately detecting and characterizing neoplasia in IBD, marking a major advance in dysplasia surveillance and cancer prevention. (PMID: 3839543810.1136/gutjnl-2023-330718)
Noguchi, T. et al. Artificial intelligence program to predict p53 mutations in ulcerative colitis-associated cancer or dysplasia. Inflamm. Bowel Dis. 28, 1072–1080 (2022). (PMID: 3527808110.1093/ibd/izab350)
Iacucci, M. et al. Endo-histo foundational fusion model: a novel artificial intelligence for assessing histologic remission and response to therapy in ulcerative colitis clinical trial. J. Crohns Colitis 19, jjaf108 (2025). The first AI model to fuse endoscopic and histologic information using foundational architectures, bringing the concept of unified endo-histo remission closer to implementation in clinical trials and routine practice. (PMID: 405813391223920210.1093/ecco-jcc/jjaf108)
Horn, V. et al. Multimodal profiling of peripheral blood identifies proliferating circulating effector CD4<sup>+</sup> T cells as predictors for response to integrin α4β7-blocking therapy in inflammatory bowel disease. Gastroenterology 168, 327–343 (2025). (PMID: 3934325010.1053/j.gastro.2024.09.021)
Preto, A. J. et al. Multi-omics data integration identifies novel biomarkers and patient subgroups in inflammatory bowel disease. J. Crohns Colitis 19, jjae197 (2025). (PMID: 397564191179289210.1093/ecco-jcc/jjae197)
Neurath, M. F. & Vieth, M. Different levels of healing in inflammatory bowel diseases: mucosal, histological, transmural, barrier and complete healing. Gut 72, 2164–2183 (2023). (PMID: 3764044310.1136/gutjnl-2023-329964)
Iacucci, M. et al. Automated real-time imaging of intestinal barrier integrity and molecular profiling for early outcome prediction in inflammatory bowel disease — Endo-Histo-Barrier-Omics study. J. Crohns Colitis 19, jjaf200 (2025). A breakthrough study showing automated, real-time barrier imaging integrated with molecular profiling to enable deep characterization and early prediction of clinical outcomes in IBD. (PMID: 412596661270188910.1093/ecco-jcc/jjaf200)
Hirten, R. P. et al. Physiological data collected from wearable devices identify and predict inflammatory bowel disease flares. Gastroenterology 168, 939–951.e5 (2025). The first major study showing that wearable-derived physiological signatures can detect and predict IBD flares in real time. (PMID: 398266191220637910.1053/j.gastro.2024.12.024)
Lee, J. W. et al. Deep learning model using stool pictures for predicting eEndoscopic mucosal inflammation in patients with ulcerative colitis. Am. J. Gastroenterol. 120, 213–224 (2025). (PMID: 3905164810.14309/ajg.0000000000002978)
Singh, S. et al. AGA living clinical practice guideline on pharmacological management of moderate-to-severe ulcerative colitis. Gastroenterology 167, 1307–1343 (2024). (PMID: 395721321216214210.1053/j.gastro.2024.10.001)
Patel, P. V. et al. Large language models outperform traditional natural language processing methods in extracting patient-reported outcomes in inflammatory bowel disease. Gastro. Hep Adv. 4, 100563 (2025). (PMID: 3987786510.1016/j.gastha.2024.10.003)
Dai, J. et al. Comparative analysis of natural language processing methodologies for classifying computed tomography enterography reports in Crohn’s disease patients. npj Digit. Med. 8, 324 (2025). (PMID: 404422941212286710.1038/s41746-025-01729-5)
Silverman, A. L. et al. Algorithmic identification of treatment-emergent adverse events from clinical notes using large language models: a pilot study in inflammatory bowel disease. Clin. Pharmacol. Ther. 115, 1391–1399 (2024). (PMID: 384597191109070910.1002/cpt.3226)
Yan, Z. et al. Ability of ChatGPT to replace doctors in patient education: cross-sectional comparative analysis of inflammatory bowel disease. J. Med. Internet Res. 27, e62857 (2025). (PMID: 401638531199752710.2196/62857)
Ozturk, O. et al. Assessing ChatGPT-v4 for guideline-concordant inflammatory bowel disease: accuracy, completeness, and temporal drift. J. Clin. Med. 14, 4599 (2025). (PMID: 406489731225003910.3390/jcm14134599)
Naqvi, H. A. et al. Evaluation of online chat-based artificial intelligence responses about inflammatory bowel disease and diet. Eur. J. Gastroenterol. Hepatol. 36, 1109–1112 (2024). (PMID: 3897352810.1097/MEG.0000000000002815)
Zhang, Y. et al. Evaluating large language models as patient education tools for inflammatory bowel disease: a comparative study. World J. Gastroenterol. 31, 102090 (2025). (PMID: 3995845011752706)
Levartovsky, A. et al. Enhancing diagnostics: ChatGPT-4 performance in ulcerative colitis endoscopic assessment. Endosc. Int. Open. 13, a-2542–0943 (2025). A key study demonstrating that LLMs can approximate expert endoscopic scoring, signalling a new frontier for AI–clinician hybrid systems.
US Food and Drug Administration. Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations — Draft Guidance for Industry and Food and Drug Administration Staff (FDA, 2025).
Omar, M. et al. Sociodemographic biases in medical decision making by large language models. Nat. Med. 31, 1873–1881 (2025). (PMID: 4019544810.1038/s41591-025-03626-6)
Stidham, R. W. & Takenaka, K. Artificial intelligence for disease assessment in inflammatory bowel disease: how will it change our practice? Gastroenterology 162, 1493–1506 (2022). (PMID: 34995537899718610.1053/j.gastro.2021.12.238)
Tham, S. et al. Knowledge, perceptions and behaviours of endoscopists towards the use of artificial intelligence-aided colonoscopy. Surg. Endosc. 37, 7395–7400 (2023). (PMID: 3767019110.1007/s00464-023-10412-3)
Urban, G. et al. Deep learning localizes and identifies polyps in real time with 96% accuracy in screening colonoscopy. Gastroenterology 155, 1069–1078.e8 (2018). (PMID: 29928897617410210.1053/j.gastro.2018.06.037)
Areia, M. et al. Cost-effectiveness of artificial intelligence for screening colonoscopy: a modelling study. Lancet Digit. Health 4, e436–e444 (2022). (PMID: 3543015110.1016/S2589-7500(22)00042-5)
Patel, H. K. et al. Lack of effectiveness of computer aided detection for colorectal neoplasia: a systematic review and meta-analysis of nonrandomized studies. Clin. Gastroenterol. Hepatol. 22, 971–980.e15 (2024). (PMID: 3805680310.1016/j.cgh.2023.11.029)
Yao, L. et al. Effect of artificial intelligence on novice-performed colonoscopy: a multicenter randomized controlled tandem study. Gastrointest. Endosc. 99, 91–99.e9 (2024). (PMID: 3753663510.1016/j.gie.2023.07.044)
Grover, S. C. & Walsh, C. M. Integrating artificial intelligence into endoscopy training: opportunities, challenges, and strategies. Lancet Gastroenterol. Hepatol. 9, 11–13 (2024). (PMID: 3783257010.1016/S2468-1253(23)00309-6)
Van Der Velden, B. H. M., Kuijf, H. J., Gilhuijs, K. G. A. & Viergever, M. A. Explainable artificial intelligence (XAI) in deep learning-based medical image analysis. Med. Image Anal. 79, 102470 (2022). (PMID: 3557682110.1016/j.media.2022.102470)
Singh, S. P., Anirvan, P. & Meher, D. Artificial intelligence in gastrointestinal endoscopy in a resource-constrained setting: a reality check. Euroasian J. Hepatogastroenterol. 10, 92–97 (2021). (PMID: 10.5005/jp-journals-10018-1322)
Norori, N., Hu, Q., Aellen, F. M., Faraci, F. D. & Tzovara, A. Addressing bias in big data and AI for health care: a call for open science. Patterns 2, 100347 (2021). (PMID: 34693373851500210.1016/j.patter.2021.100347)
Nigam, G. et al. Survey on the use of artificial intelligence in IBD patients in the USA and UK [abstract PMO-10]. Gut 70, A80 (2021).
Heidt, A. Intellectual property and data privacy: the hidden risks of AI. Nature https://doi.org/10.1038/d41586-024-02838-z (2024).
Kamulegeya, L. et al. Using artificial intelligence on dermatology conditions in Uganda: a case for diversity in training data sets for machine learning. Afr. Health Sci. 23, 753–763 (2023). (PMID: 382235941078228910.4314/ahs.v23i2.86)
Huanbutta, K. et al. Artificial intelligence-driven pharmaceutical industry: a paradigm shift in drug discovery, formulation development, manufacturing, quality control, and post-market surveillance. Eur. J. Pharm. Sci. 203, 106938 (2024). (PMID: 3941912910.1016/j.ejps.2024.106938)
Chhina, A. et al. Revolutionizing pharmaceutical industry: the radical impact of artificial intelligence and machine learning. Curr. Pharm. Des. 29, 1645–1658 (2023). (PMID: 3755090410.2174/1381612829666230807161421)
Lee, D. & Yoon, S. N. Application of artificial intelligence-based technologies in the healthcare industry: opportunities and challenges. Int. J. Environ. Res. Pubic Health 18, 271 (2021). (PMID: 10.3390/ijerph18010271)
Richie, C. Environmentally sustainable development and use of artificial intelligence in health care. Bioethics 36, 547–555 (2022). (PMID: 35290675931165410.1111/bioe.13018)
Ueda, D. et al. Climate change and artificial intelligence in healthcare: review and recommendations towards a sustainable future. Diagn. Interv. Imaging 105, 453–459 (2024). (PMID: 3891812310.1016/j.diii.2024.06.002)
Sarkar, S. et al. Carbon footprint reduction for sustainable data centers in real-time. In Proc. 38th AAAI Conf. Artif. Intell. 22322–22330 (AAAI Press, 2024).
Maeda, Y. et al. Fully automated diagnostic system with artificial intelligence using endocytoscopy to identify the presence of histologic inflammation associated with ulcerative colitis (with video). Gastrointest. Endosc. 89, 408–415 (2019). (PMID: 3026854210.1016/j.gie.2018.09.024)
Bossuyt, P. et al. Automatic, computer-aided determination of endoscopic and histological inflammation in patients with mild to moderate ulcerative colitis based on red density. Gut 69, 1778–1786 (2020). (PMID: 3191523710.1136/gutjnl-2019-320056)
Seager, A. et al. Polyp detection with colonoscopy assisted by the GI Genius artificial intelligence endoscopy module compared with standard colonoscopy in routine colonoscopy practice (COLO-DETECT): a multicentre, open-label, parallel-arm, pragmatic randomised controlled trial. Lancet Gastroenterol. Hepatol. 9, 911–923 (2024). (PMID: 3915349110.1016/S2468-1253(24)00161-4)
White, C. D. et al. A deep learning approach to case prioritisation of colorectal biopsies. Histopathology 86, 373–384 (2025). (PMID: 3936057910.1111/his.15331)
Wei, Y. et al. Focal liver lesion diagnosis with deep learning and multistage CT imaging. Nat. Commun. 15, 7040 (2024). (PMID: 391477671132734410.1038/s41467-024-51260-6)
Mannucci, A. et al. Prediction of long-term recurrence-free and overall survival in early-onset colorectal cancer: the ENCORE multi-centre study. npj Precis. Oncol. 9, 202 (2025). (PMID: 405441801218258810.1038/s41698-025-00978-7)
Jiang, X. et al. End-to-end prognostication in colorectal cancer by deep learning: a retrospective, multicentre study. Lancet Digit. Health 6, e33–e43 (2024). (PMID: 3812325410.1016/S2589-7500(23)00208-X)
Higgins, K. et al. The Helicobacter pylori AI-clinician harnesses artificial intelligence to personalise H. pylori treatment recommendations. Nat. Commun. 16, 6472 (2025). (PMID: 406596121225989910.1038/s41467-025-61329-5)
Entry Date(s):
Date Created: 20260320 Latest Revision: 20260320
Update Code:
20260320
DOI:
10.1038/s41575-026-01190-z
PMID:
41857227
Database:
MEDLINE
*Further Information*
*Artificial intelligence (AI) is rapidly transforming the management landscape of inflammatory bowel disease (IBD). While early applications in endoscopy, digital pathology and cross-sectional imaging drew substantial attention, next-generation AI systems that enable deeper disease understanding, personalized treatment and streamlined clinical workflows are now emerging. These advances encompass the multimodal integration of endoscopic, histological and molecular data ('endo-histo-omics'); AI-assisted assessment of the intestinal barrier; remote monitoring via wearables; and the incorporation of large language models for decision-making support and patient interactions. This Perspective traces the evolution of AI in IBD from domain-specific tools to foundational platforms supporting data-driven precision medicine. We highlight validated AI applications across diagnosis, monitoring, outcome prediction and neoplasia surveillance. We also explore the expectations of key stakeholders, including clinicians, patients, regulatory bodies and industry, and discuss unresolved challenges such as explainability, integration into workflows, reimbursement and environmental sustainability. By aligning innovation with ethical and clinical priorities, AI holds the potential to redefine IBD care. Its future will be shaped by collaboration, transparency and responsible implementation, ushering in a new era of personalized, efficient and equitable care for individuals with IBD.
(© 2026. Springer Nature Limited.)*
*Competing interests: The authors declare no competing interests.*